^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

YPN-005

i
Other names: YPN-005, YPN 005, YPN005
Company:
KT&G Corp
Drug class:
CDK7 inhibitor
over1year
Antileukemic effect of cyclin-dependent kinase 7 inhibitor; YPN-005 combined with FLT3 inhibitor in FMS-tyrosine kinase 3 -mutated acute myeloid leukemia (ICKSH 2023)
FLT3-TKIs include midostaurin, gilteritinib, and quizartinib. These results provide preclinical evidence of combined treatment of YPN-005 and FLT3 inhibitor for therapeutic strategies for FLT3-mutated AML. Keyword : FLT3-ITD, CDK7 inhibitor, Mitochondrial dysfunction, Apoptosis
PARP Biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3) • CDK7 (Cyclin Dependent Kinase 7) • ANXA5 (Annexin A5)
|
FLT3-ITD mutation • FLT3 mutation • MYC expression • MCL1 expression • FLT3-ITD expression
|
Xospata (gilteritinib) • Rydapt (midostaurin) • Vanflyta (quizartinib) • YPN-005
2years
Antileukemic activity of YPN-005, a CDK7 inhibitor, inducing apoptosis through c-MYC and FLT3 suppression in acute myeloid leukemia. (PubMed, Heliyon)
Phosphorylated FLT3/Signal transducer and activator of transcription 5 (STAT5) was decreased and FLT3/STAT5 was downregulated with YPN-005 treatment. Our data suggest that YPN-005 has a role in treating AML by suppressing c-MYC and FLT3.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
FLT3-ITD mutation • MYC expression
|
YPN-005